严重烧伤患者血浆和烧伤焦痂中的米卡芬净浓度。
Micafungin concentrations in the plasma and burn eschar of severely burned patients.
机构信息
Department of Emergency and Critical Care Medicine, School of Medicine, Keio University, Tokyo, Japan.
出版信息
Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5. doi: 10.1128/AAC.05381-11. Epub 2011 Nov 14.
Abstract
Micafungin concentrations in plasma and burn eschar after daily intravenous infusion (1 h) of micafungin (200 to 300 mg) were investigated for six patients with severe burns. Micafungin treatment was initiated more than 72 h after the burn injuries. The peak and trough levels in the plasma after the initial administration and repeated administrations for more than 4 days were comparable with or slightly lower than the reported values for healthy volunteers. Micafungin concentrations in the plasma and burn eschar were between 3.6 and >1,000 times higher than the reported MIC(90)s of micafungin against clinically important Candida and Aspergillus species.
摘要
对 6 例严重烧伤患者进行了每日静脉输注（1 小时）米卡芬净（200 至 300mg）后血浆和烧伤焦痂中的米卡芬净浓度的研究。米卡芬净治疗在烧伤后超过 72 小时开始。初始给药后和多次给药超过 4 天的血浆峰浓度和谷浓度与健康志愿者的报道值相当或略低。米卡芬净在血浆和烧伤焦痂中的浓度比米卡芬净对临床相关念珠菌和曲霉菌的报道 MIC（90）高 3.6 至> 1000 倍。
相似文献
1
Micafungin concentrations in the plasma and burn eschar of severely burned patients.
Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5. doi: 10.1128/AAC.05381-11. Epub 2011 Nov 14.
2
Penetration of micafungin into the burn eschar in patients with severe burns.
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):93-7. doi: 10.1007/s13318-013-0146-9. Epub 2013 Jun 15.
3
Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5914-21. doi: 10.1128/AAC.00727-16. Print 2016 Oct.
4
Bronchopulmonary disposition of micafungin in healthy adult volunteers.
Antimicrob Agents Chemother. 2009 Mar;53(3):1218-20. doi: 10.1128/AAC.01386-08. Epub 2008 Dec 29.
5
Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.
Intensive Care Med. 2015 Feb;41(2):371-2. doi: 10.1007/s00134-014-3586-z. Epub 2014 Dec 3.
6
Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.
Antimicrob Agents Chemother. 2010 Aug;54(8):3451-9. doi: 10.1128/AAC.01647-09. Epub 2010 May 3.
7
Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62. doi: 10.1016/j.bbmt.2010.05.002. Epub 2010 Jun 20.
8
Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.
J Infect Chemother. 2011 Oct;17(5):731-4. doi: 10.1007/s10156-011-0240-3. Epub 2011 May 3.
9
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9. doi: 10.1128/AAC.00623-15. Epub 2015 May 11.
10
Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
Future Microbiol. 2016;11(4):485-90. doi: 10.2217/fmb.16.3. Epub 2016 Apr 12.
引用本文的文献
1
Penetration of echinocandins into wound secretion of critically ill patients.
Infection. 2021 Aug;49(4):747-755. doi: 10.1007/s15010-021-01604-x. Epub 2021 Apr 20.
2
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.
Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5.
3
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12.
4
Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5914-21. doi: 10.1128/AAC.00727-16. Print 2016 Oct.
5
[Not Available].
Ann Burns Fire Disasters. 2015 Mar 31;28(1):21-8.
6
Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.
Intensive Care Med. 2015 Feb;41(2):371-2. doi: 10.1007/s00134-014-3586-z. Epub 2014 Dec 3.
7
Penetration of micafungin into the burn eschar in patients with severe burns.
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):93-7. doi: 10.1007/s13318-013-0146-9. Epub 2013 Jun 15.
本文引用的文献
1
Candidemia and invasive candidiasis: a review of the literature for the burns surgeon.
Burns. 2011 Mar;37(2):181-95. doi: 10.1016/j.burns.2010.01.005. Epub 2010 Apr 14.
2
Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.
Clinics (Sao Paulo). 2010 Feb;65(2):237-43. doi: 10.1590/S1807-59322010000200017.
3
Candida in burns: risk factors and outcomes.
J Burn Care Res. 2010 Mar-Apr;31(2):257-63. doi: 10.1097/BCR.0b013e3181d0f536.
4
Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm.
J Infect Chemother. 2009 Aug;15(4):219-27. doi: 10.1007/s10156-009-0689-5. Epub 2009 Aug 18.
5
Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.
Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):191-8. doi: 10.1007/BF03191118.
6
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Clin Pharmacokinet. 2008;47(10):635-54. doi: 10.2165/00003088-200847100-00002.
7
Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.
Drug Metab Pharmacokinet. 2006 Aug;21(4):324-31. doi: 10.2133/dmpk.21.324.
8
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.
Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002.
9
Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
J Clin Pharmacol. 2005 Oct;45(10):1145-52. doi: 10.1177/0091270005279580.
10
Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.
Biol Pharm Bull. 2004 Jul;27(7):1154-6. doi: 10.1248/bpb.27.1154.
Zotero 插件